Stockwinners Market Radar for May 11, 2017 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:15 EDT Netflix announces 400 new jobs in Europe, two new European originals - Netflix announced earlier the creation of 400 jobs at its new European customer service hub which opened this week in Amsterdam. Supporting customers across 11 European countries, the multilingual hub will employ initially a workforce of 170, growing to 345 by the end of 2017 and surpassing 400 by the end of 2018. The company also confirmed plans to announce at least six new European original projects before the end of 2017. The first of these, "Dogs of Berlin," was announced on April 28 and will be written, produced and shot in Germany before launching in 2018. The second, a new French original called "Osmosis," was announced today and is expected to begin production in France in 2018. "Europe is a creative centre for great storytelling that resonates around the world and we continue to invest in European content," said Reed Hastings, Netflix co-founder and CEO. Reference Link

18:25 EDT Kona Grill CEO acquires 50,000 common shares - In a regulatory filing, Kona Grill president and CEO Berke Bakay disclosed the purchase of 50,000 common shares for $4.8344 per share.

18:03 EDT On The Fly: After Hours Movers - UP AFTER EARNINGS: Trade Desk (TTD), up 18.1%... Finjan Holdings (FNJN), up 16.2%... CA Technologies (CA), up 4.1%. ALSO HIGHER: Hain Celestial (HAIN), up 4.8% after it filed to delay its 10-Q and said that its accounting review is close to completion... Pandora (P), up 1.9% after Point72 Asset Management disclosed a 5.4% passive stake in the company. DOWN AFTER EARNINGS: voxeljet (VJET), down 14.7%... ChromaDex (CDXC), down 9%... CyberArk (CYBR), down 6.6%... Darling Ingredients (DAR), down 6.2%... Presidio (PSDO), down 6%... Nordstrom (JWN), down 3.8%. ALSO LOWER: Akari Therapeutics (AKTX), down 17.2% after chief executive officer Gur Roshwalb was placed on administrative leave as an ad hod special committee conducts its review of the involvement, if any, of company personnel with the "Edison Report"... Spark Therapeutics (ONCE), down 1.5% after it commenced an offering of 840,000 shares in a Block Trade.

17:51 EDT Expedia to acquire majority stake in SilverRail Technologies - Expedia and SilverRail Technologies announced entry into a definitive agreement in which Expedia will acquire a majority stake in SilverRail. SilverRail set out to solve rail's most challenging technology problems and has been an important Expedia industry partner, helping to bring online booking for rail to Expedia's customers. SilverRail will remain focused on transforming the consumer experience of rail for carriers, travel retailers, and corporate travel companies. The transaction is anticipated to close in the middle of 2017 pending satisfaction of closing conditions, including approval from the relevant competition authority.

17:46 EDT Nordstrom: May be opportunities to close stores, but not part of strategy - Asked during the company's Q1 earnings conference call about what they consider "ideal" store footprint over the next three to five years, Nordstrom executives said, "For full line stores, we have roughly 120 stores today. It's a healthy fleet... While there may be opportunities to close underperforming stores, that's not really part of our strategy. We don't have a closure strategy. We have a market share strategy. As we look at any given market, there might be an opportunity to move from a C location to an A location, as an example. There might be opportunities to look at the number of stores we have in a given market, but what we're not going to look at is just simply the four-wall economics of that store -- we're going to look at how good of a job we're doing using and leveraging those stores."

17:35 EDT Nordstrom: Hearing Jet.com acquired Bonobos - "Some of our folks have had good relationships with the Jet.com folks and have been in communication with them since that acquisition got announced. The Bonobos experience has been a good one for us. What we're hearing is Jet.com bought [Bonobos], not Wal-Mart (WMT), and they're looking to keep those brands. So for right now, we don't see any change in our Bonobos relationship," Nordstrom said in its Q1 earnings conference call.

17:30 EDT Boeing awarded $488M government contract modification - The Boeing Co., Mesa, Arizona, was awarded a $488,076,762 modification to foreign military sales contract for the remanufacture of 38 AH-64 Apache aircraft, and to procure three Longbow crew trainers and associated spares. Work will be performed in Mesa, Arizona, with an estimated completion date of May 31, 2024. Fiscal 2010 other funds in the amount of $488,076,762 were obligated at the time of the award. U.S. Army Contracting Command, Redstone Arsenal, Alabama, is the contracting activity.

17:25 EDT comScore files form to delay 10-Q - The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date.

17:17 EDT Orbital ATK files to delay Form 10-Q - In a regulatory filing, Orbital ATK said that it is unable to file its Quarterly Report on Form 10-Q for the quarter ended April 2, 2017 within the prescribed time period without unreasonable effort or expense.

17:09 EDT Hain Celestial files for delayed 10-Q, says accounting review nearing completion - Hain Celestial noted in its regulatory filing: "As previously disclosed... during 4Q16, the company identified concessions that were granted to certain distributors in the U.S. and commenced an internal accounting review in order to determine whether the revenue associated with those concessions was accounted for in the correct period and to evaluate its internal control over financial reporting... At this time, the company believes that its internal accounting review is nearing completion. The company presently anticipates that it will be in a position to file its Form 10-Q together with its annual report on Form 10-K for the fiscal year ended June 30, 2016, its quarterly report on Form 10-Q for the quarter ended September 30, 2016 and its quarterly report on Form 10-Q for the quarter ended December 31, 2016 by the end of May."

17:03 EDT HC2 Holdings says portfolio company DBM to move up dividend payment - HC2 Holdings announced that its operating subsidiary DBM Global will move up its previously announced cash dividend of $1.29 per share from June 5 to May 30. The dividend will be paid to DBM Global stockholders of record at the close of business on May 19. HC2, as the largest stockholder of DBM Global, expects to receive approximately $4.5M of the total $5.0M dividend payout.

17:02 EDT Mitel signs MoU with Toshiba to transfer communications systems business assets - Mitel (MITL) confirmed it has signed a Memorandum of Understanding to transfer certain assets and support obligations, including existing inventory, from Toshiba Corporation (TOSBF) to Mitel. This follows Toshiba's decision earlier this year to exit the market. The transaction will provide Toshiba customers and partners a clear path forward with Mitel, a global leader in Unified Communications and Collaborations. Combined with the transfer of existing inventory, the MoU also contemplates a transition services agreement ensuring product and service continuity for Toshiba customers. Both companies are committed to supporting warranty and maintenance obligations. The transaction is expected to be immediately accretive. Additional financial terms of the deal were not disclosed. This transaction is subject to completion of definitive documentation and other customary conditions. The transaction is expected to be completed early this summer.

16:59 EDT Nordstrom: Margin impacted by additional markdowns on slower-moving Rack items

16:54 EDT American Midstream Partners files form to delaty 10-K - American Midstream Partners is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q for the quarter ended March 31, on or before May 10. On March 8, the Partnership completed the acquisition of JP Energy Partners, an entity controlled by affiliates of ArcLight Capital Partners, LLC in a unit-for-unit merger. After the completion of the JPE Acquisition, the Partnership realigned the composition of the reportable segments to focus operational and commercial efforts for maximum effectiveness. As a result, management needs additional time to complete the Partnership's consolidated financial statements. The Partnership intends to file the Form 10-Q within the time period prescribed in Rule 12b-25 promulgated under the Securities Exchange Act of 1934 .

16:51 EDT Nordstrom: 'Not satisfied' with top-line results - Nordstrom executives are speaking on the company's Q1 earnings conference call.

16:44 EDT Edenbrook raises stake in YuMe to 7.06% from 6.31%

16:33 EDT National Bankshares announces retirement of CEO James Rakes - On May 9, James G. Rakes announced at the annual shareholders meeting of National Bankshares that effective August 31 he will retire from his positions as President and Chief Executive Officer of the Company and as Chairman of the Board of Directors of the Company's wholly owned banking subsidiary, the National Bank of Blacksburg , and as President, Chief Executive Officer and director of National Bankshares Financial Services, the Company's wholly owned financial services subsidiary. Mr. Rakes has been President and Chief Executive Officer and a director of the Company since its founding. He has served as President and Chief Executive Officer of the National Bank from 1983 until early in 2014. Mr. Rakes will continue to serve on the Company's Board of Directors through his current term, which ends at the Company's annual shareholders meeting in 2019. The Board of Directors of the Company announced that Mr. Rakes has agreed to remain as the Chairman of the Company's Board of Directors until the end of his current term in order to continue to provide the Company and the Board of Directors with the valuable benefit of his leadership based on over 30 years of experience in the executive management of the Company and its subsidiaries

16:32 EDT Darling Ingredients CEO says 'off to a good start in 2017' - "We capitalized on an improved environment with our first quarter results reflecting solid execution across our global platform leveraged by sequentially consistent and improved performance in our Feed and Food segments. Sequentially, Fuel segment results reflect the lack of the blenders tax credit and one-time settlements received last quarter," said Randall C. Stuewe, Chairman and CEO of Darling Ingredients Inc. "Diamond Green Diesel completed its second maintenance turnaround and issued a partner dividend of $25 million each. Our planned expansion of Diamond Green Diesel is progressing well and we continue to focus on growing our global platform while improving efficiencies and increasing capital returns. We're off to a good start in 2017."

16:23 EDT RA Pharmaceuticals sees mid-year RA101495 Phase 2 initial data release - "We continue to advance our lead compound, RA101495, and we recently commenced dosing in our Phase 2 program in paroxysmal nocturnal hemoglobinuria... We look forward to sharing initial data from these Phase 2 studies mid-year 2017 and additional results at year-end. We are also investigating RA101495 in other complement-mediated diseases such as myasthenia gravis and lupus nephritis. We plan to initiate a Phase 2 trial in MG and a Phase 1b clinical trial supporting development in LN in 2H17. We look forward to updating you on our RA101495 development plans, our orally-available small molecule C5 inhibitors and other pipeline program," says RA.

16:22 EDT Gabelli raises Armstrong Flooring stake to 8.13% from 7.11%

16:20 EDT Portolan Capital reports 5.13% passive stake in Care.com

16:20 EDT Akari places CEO on administrative leave as committee conducts review - In a regulatory filing, Akari Therapeutics disclosed that the company's board of directors has established an ad hoc special committee of the board to review the involvement, if any, of company personnel with the "Edison Report." As previously reported by Akari on April 27, the company issued a press release stating that Edison Investment Research has withdrawn its report issued April 26 titled "Akari's Coversin matches Soliris in Phase II, known as the "Edison Report," because it "contains material inaccuracies, including without limitation, with respect to Akari's recently announced interim analysis of its ongoing Phase 2 PNH trial of Coversin." Investors were cautioned not to rely upon any information contained in the Edison Report and instead were directed to Akari's press release issued on April 24 that discusses the interim analysis of its ongoing Phase 2 PNH trial and other matters. While the ad hoc review is pending, Dr. Gur Roshwalb, the company's Chief Executive Officer, has been placed on administrative leave and Dr. Ray Prudo in his role as Executive Chairman is temporarily assuming Dr. Roshwalb's duties in his absence, Akari noted.

16:19 EDT Point72 Asset Management rports 5.4% passive stake in Pandora

16:17 EDT Hennessy Advisors Inc to acquire Rainier U.S. equity funds - Hennessy Advisors (HNNA) announced that it has signed a definitive agreement with Manning & Napier Group (MN) and Rainier Investment Management to purchase the assets related to the management of three Rainier Funds, including the Rainier Mid Cap Equity Fund, the Rainier Small/Mid Cap Equity Fund, and the Rainier Large Cap Equity Fund. The Rainier U.S. Funds currently have assets of approximately $565M. The transaction is expected to be completed in the third quarter of 2017.

16:14 EDT Universal Display unit Adesis buys Delaware facility to expand operations - Universal Display announced that its wholly-owned subsidiary, Adesis Inc., purchased its New Castle, Delaware building, to expand its custom organic synthesis, research & development, and specialty manufacturing capabilities. The New Castle, DE facility is a 47,500-square-foot building in the Southgate Industrial Center, of which Adesis had previously leased about 25,100 square feet.

16:14 EDT Selecta Biosciences begins dosing in trial of SELA-070 - Selecta Biosciencesannounced that patient dosing has commenced in a Phase 1 clinical trial to assess the safety, tolerability and pharmacodynamic profile of SELA-070, a nicotine vaccine candidate in development for smoking cessation and relapse prevention. The project is being funded primarily by an $8 million grant from the National Institute on Drug Abuse, part of NIH. Selecta's Synthetic Vaccine Particles, SVP, technology is designed to be a versatile platform and is being utilized in a series of programs aimed at inducing either antigen-specific immune tolerance or immune stimulation. SELA-070, an immune stimulation product candidate, delivers nicotine conjugated to the surface of nanoparticles that encapsulate immune stimulating agents. This second-generation product candidate is intended to induce a strong and durable immune response by triggering the production of a high level of anti-nicotine antibodies that bind to the nicotine inhaled by smokers, thus preventing nicotine from crossing the blood-brain barrier and triggering an addictive response. "Smoking continues to profoundly impact our society and remains as one of our greatest public health challenges," said Werner Cautreels, Ph.D., CEO and Chairman of Selecta. "We are very proud and motivated to be teaming with NIDA on this trial to determine if SELA-070 might benefit the millions of smokers in the U.S. and worldwide who are seeking ways to overcome their addiction and improve their health." Approved by the Federal Agency for Medicines and Health Products in Belgium, the Phase 1 trial is a double-blind, placebo-controlled, dose escalation study that is expected to enroll 48 smokers in Belgium. Patients will receive three injections of SELA-070 or a placebo over a period of 12 weeks followed by 8 weeks of monitoring. In addition to safety, the study will evaluate the vaccine's potency through the measurement of concentrations of nicotine-specific antibodies.

16:11 EDT DHCS selects Allscripts technology to support national health care surveys - The National Center for Health Statistics, Division of Health Care Statistics, DHCS, selected Allscripts as part of a team to provide data technology and services for United States National Health Care Surveys. The team is led by prime contractor ICF, a leading provider of professional services and technology-based solutions to government and commercial clients. The contract is a Blanket Purchase Agreement, signed in late 2016, with a total period of performance of five years. Allscripts technology, such as dbMotion(TM) Solution, and services will be available to support the mission of DHCS, which is collecting, monitoring, analyzing and disseminating data on the use, access, quality, safety, disparity and cost of health care in the United States and on the healthcare organizations and professionals who deliver that care. DHCS conducts the National Health Care Surveys, a family of nationally representative surveys of healthcare providers in inpatient, outpatient, ambulatory and long-term care settings. Providers, policy makers and researchers use the data from the surveys to address important topics in healthcare, including the quality and disparities of care among populations, epidemiology of medical conditions, diffusion of technologies, effects of policies and practice guidelines, and changes in healthcare over time.

16:05 EDT CyberArk acquires DevOps security firm Conjur for $42M - CyberArk Software acquired privately-held Conjur, a Newton, Mass.-based provider of DevOps security software, for $42M in cash. "Conjur's revolutionary technology for securing DevOps extends CyberArk's reach deeper into the DevOps lifecycle to protect secrets and manage machine identities," the company remarked. The CyberArk-Conjur Solution for DevOps is available from CyberArk today.

16:02 EDT Akari Therapeutics trading halted, news pending

15:42 EDT Live Nation announces exclusive touring partnership with Jay Z - Shawn "Jay Z" Carter and Live Nation announced an exclusive touring pact, which continues their longstanding partnership. The deal includes worldwide touring, in which Live Nation will produce and promote JAY Z concert events. "Live Nation and I entered unchartered territory in 2008. Over 9 years, we have traveled the world producing historic music experiences. Michael Rapino is an industry visionary, and this renewed partnership is a testament to our longstanding relationship and the talented individuals at Live Nation. For the next 10 years, we will continue redefining the live event landscape," stated Carter.

14:46 EDT Elliott issues new Arconic presentation, highlights lack of reincorporation push - Elliott Management, which manages funds that collectively own a 13.2% economic interest in Arconic, today released an investor presentation entitled "A New Arconic: An Opportunity for Real Change on May 25th." Elliott noted that "the presentation highlights the opportunity for Arconic shareholders to put in place board leadership capable of bringing real change by voting for the shareholder nominees... The four highly qualified, independent shareholder nominees are an ideal mix of successful operators and proven change agents. In its most recent letter to investors, Arconic's board made a significant admission: Despite appearing to realize that reincorporation in Delaware is the surest path to implementing the best-in-class corporate-governance practices that Arconic's shareholders deserve, the board declined to pursue reincorporation this year because it could have 'substantially impacted its ability to compete with Elliott for shareholder support in the proxy contest.' While Arconic's board is obsessively focused on 'winning' a proxy contest with its shareholders, as this presentation makes clear, Elliott is focused on real change that will benefit all of Arconic's stakeholders and create value over the long term."

14:32 EDT Quidel wins FDA approval for Solana C. difficile Assay - Quidel Corporation announced that it has received 510k clearance from the United States Food and Drug Administration to market its Solana C. difficile Assay for the direct, qualitative detection of the Clostridium difficile DNA in unformed stool specimens of patients suspected of having Clostridium difficile-infection. Clostridium difficile is the most frequently identified enteric pathogen in patients with antibiotic-associated diarrhea and colitis. Per the Centers for Disease Control and Prevention, C. difficile was responsible for approximately half a million infections in the United States in 2011, with 29,000 patient deaths occurring shortly after the initial diagnosis.

14:18 EDT Snap plunges after first post-IPO earnings as user growth disappoints - Shares of Snap Inc. (SNAP) are sliding after the parent of Snapchat reported quarterly results for the first time as a public company, posting lower than expected revenue and announcing slower than expected user growth. Following the news, several Wall Street analysts cut their targets on the shares, while Oppenheimer and Cantor upgraded Snap to Outperform and to Neutral, respectively. RESULTS: Last night, Snap reported first quarter revenue $149.65M, which was worse than the expected $157.98M. The company also announced that first quarter daily average users, or DAUs, were up 36% year over year to 166M, and up 5% quarter over quarter. Additionally, first quarter average revenues per user, or ARPU, was up 181% year over year, but down 14% quarter over quarter to 90c. SNAP UPGRADES: In a post-earnings note, Oppenheimer analyst Jason Helfstein upgraded Snap to Outperform from Perform, with a $23 price target on the shares, after the stock fell in after-hours trading on quarterly results. Many analysts ignored Snap's prospectus disclosure that suggested sequentially declining revenue in the first quarter, the analyst told investors, while noting that the company's products will continue to be made "for universal use, not tailored toward on-boarding older users." His peer at Cantor also upgraded the stock this morning to Neutral from Underweight, with a $17 price target, citing similar reasons. Analyst Kip Paulson said in a note of his own that although intense competition for users and digital brand dollars from entities such as Facebook (FB), Alphabet's (GOOG; GOOGL) YouTube, and Twitter (TWTR) may continue, Snap still has a rich and engaging canvas for brand advertisers that are targeting the hard-to-reach, but "highly desirable," 18-34 year-old demo, and valuation has improved post selloff. ANALYST DEFENSE: Meanwhile, JMP Securities analyst Ronald Josey recommended buying Snap on weakness, arguing that its engagement continues to increase, and as he continues to believe the company's ARPU can rise closer to that of Facebook. Jefferies analyst Brian Fitzgerald also kept a Buy rating and a $30 price target on Snap's shares, highlighting the company's DAU and ARPU growth year over year. While he acknowledged that expected seasonality in revenue led to a quarter over quarter decline in ARPU, he expects Snap to buck that trend as it continues to drive engagement and offers advertisers better targeting capability. Moreover, the analyst said he sees opportunities to increase ad load and noted that Snap's asset light business model allows the flexibility to focus on innovation. PRICE TARGET CUTS: Not all analysts were as bullish on Snap after earnings, with many lowering their price targets on the shares. JPMorgan analyst Doug Anmuth was one of them, cutting his price target for Snap to $20 from $24 and noting that he believes the Street wanted more quarter over quarter revenue growth. The analyst also pointed out that it is "very early for the business side of Snap" as there is still a "tremendous amount to do," especially in building out the ad platform. He reiterated a Neutral rating on the stock. His peer at Piper Jaffray also lowered his price target on Snap's shares to $20 from $23, while keeping a Neutral rating on the name, as he sees its user growth and ad load ramp as being "underwhelming" given the company's valuation. Further, analyst Samuel Kemp said he views the company's valuation as baking in "massive success" in scaling ad load and no negative ramifications from expanding use cases at Facebook's properties. Additionally, Barclays, Deutsche Bank and Citi cut their price targets for Snap this morning to $18, $23 and $24, respectively. PRICE ACTION: In afternoon trading, shares of Snap have plunged over 21% to $18.04. After pricing its IPO at $17 per share on March 2, Snap finished its first day of trading with an advance of about 44%, closing at $24.51 per share.

14:10 EDT Caterpillar rises as BofA bets on guidance hike, dividend raise - Shares of Caterpillar (CAT) are advancing following a Bank of America upgrade of the construction equipment manufacturer ahead of its next earnings report, which is predicted to be another "beat and raise," and a potential dividend increase. WHAT'S NEW: Bank of America Merrill Lynch analyst Ross Gilardi upgraded Caterpillar to Buy from Neutral and raised his price target on the shares to $120 from $105, citing the company's continued acceleration of monthly retail sales, a potential dividend raise over the summer, his expectations for another big beat and raise in July and the chance that the company's September investor day meeting will provide a further catalyst. Caterpillar's retail sales "are likely to serve as a positive catalyst through the year" as end-user machinery demand continues to increase and investors should expect another big beat in the second quarter as Caterpillar's fiscal year 2017 outlook "seems conservative," Gilardi wrote. He added that there are increasing chances of Caterpillar raising its dividend over the summer as the company "gains confidence in an inflection point" and it looks to shift capital allocation priorities from balance sheet preservation to the dividend and more active M&A. The company's investor day, which is the first in four years and will be hosted under new CEO Jim Umpleby, will focus on more disciplined capital spending, returns, sustainable dividend increases, small to mid-sized M&A, pricing over volume, reduced cyclicality, the company's digital opportunity, and a refocus on the rental strategy, the analyst wrote. WHAT'S NOTABLE: Wells Fargo analyst Andrew Casey maintained an Outperform rating on Caterpillar in April, saying the first quarter of 2017 is the first in a string of quarters in which Caterpillar should realize higher earnings power as backlog growth should continue driven by end market demand, end market growth and a reversal of inventory restocking. Casey also raised his price target range on the stock to $120-$123 from $116-119. Credit Suisse analyst Jamie Cook also maintained an Outperform rating and raised Caterpillar's target price to $123 from $111 after earnings in April, saying the company gave "conservative guidance" and was "off to a great start and set up well for 2017." PRICE ACTION: Shares of Caterpillar are up 1% to $101.39 in afternoon trading.

13:31 EDT Connecticut Water raises quarterly dividend 5.3% to 29.75c per share - Connecticut Water Service announces that the company's board of directors has approved an increase of 5.3% in its annualized cash dividend, raising the quarterly amount to 29.75c per share on the company's common stock for an annualized dividend of $1.19. CTWS's dividend has increased by more than 20% since 2013, and today's announcement marks the 48th consecutive year of increasing dividend payments. CTWS is included in the NASDAQ Dividend Achievers Select Index, which requires a minimum of 10 consecutive years of dividend increases.

13:21 EDT Microsoft unveils Windows Mixed Reality motion controllers - Microsoft unveiled the "Windows Mixed Reality motion controllers" at day two of its developer conference. The product launches this holiday. Reference Link

13:11 EDT Emerson announces additional $63M expansion for InSinkErator in Wisconsin - Emerson announced the launch of an additional $63M in strategic investments for InSinkErator's Southeast Wisconsin operations, including nearly $34M for a new headquarters and lab facility to be built in Mount Pleasant, along with $29M in planned improvements at InSinkErator's manufacturing facility in Racine. Construction of the new headquarters and lab building is scheduled to begin next month. The new 85,000-square-foot, two-story building will house 175 engineers and professional staff located at InSinkErator's current headquarters in Racine.

13:06 EDT Boston Scientific says real-world study of S-ICD shows positive outcomes - Boston Scientific announced results from the U.S. post-market approval study evaluating real-world patients implanted with the Subcutaneous Implantable Defibrillator System, the largest S-ICD study to date. Data collected from the study were presented at Heart Rhythm 2017, the Heart Rhythm Society's 38th Annual Scientific Sessions, and demonstrated that physicians are implanting the S-ICD System largely for patients typically treated with transvenous implantable cardioverter defibrillators as well as for sicker patients while achieving a high success rate and low complication rate. Acute results demonstrate the therapy effectively terminated life-threatening heart arrhythmias in 98.7% of evaluated patients. The S-ICD System analysis also validated low complication rates, with a complication-free rate of 96.2% at 30 days post-procedure. The non-randomized registry, initiated in 2012 after the S-ICD System received U.S. Food and Drug Administration approval, included 1,637 patients implanted with the device at 86 U.S. medical centers. "Beyond the positive clinical outcomes, we are also seeing advancements in procedural techniques as physician experience and confidence continue to build. Physicians are implanting over half of the devices with two surgical incisions rather than the standard three incisions and avoiding use of general anesthesia in more than one-third of patients," the company noted.

13:01 EDT MasterCard collaborates with Verifone, Global Payments over EMV experience - MasterCard (MA) said it is joining forces with payments industry leaders to enhance and expedite the consumer checkout experience leveraging the company's M/Chip Fast technology. M/Chip Fast prioritizes the parts of a transaction critical to security to speed chip checkout times. Verifone (PAY) intends to incorporate M/Chip Fast into its products deployed in the United States. Verifone products, including the FIPay line, are used by most of the top 200 U.S. retailers and will help drive greater adoption of faster EMV technology. "Verifone is committed to creating faster and easier payment experiences for merchants and their customers. This collaboration with Mastercard covers a myriad of different use cases across a range of retail verticals," said Paul Galant, chief operating officer of Verifone. Global Payments (GPN) will make the faster EMV technology available to key merchants in the fast food, grocery, transit and other retail environments, where speed is critical to the consumer experience.

12:37 EDT Orin Hirschman reports 5.1% passive stake in Vuzix

12:14 EDT SEC charges former MDC Partners CEO with failing to disclose perks to investors - The Securities and Exchange Commission announced that the former CEO of a marketing company has agreed to pay $5.5M to settle charges that his perks were not properly disclosed to shareholders. According to the SEC's order, shareholders were informed in annual filings that Miles S. Nadal received an annual perquisite allowance of $500,000 in addition to other benefits as the chairman and CEO of MDC Partners. But the SEC's investigation found that without disclosing information to investors as required, MDC Partners paid for Nadal's personal use of private airplanes as well as charitable donations in his name, yacht and sports car expenses, cosmetic surgery, and a wide range of other perks. All total, Nadal improperly obtained an additional $11.285M in perks beyond his disclosed benefits and $500,000 annual allowances. He has since resigned and returned $11.285M to the company.

11:56 EDT Groupe Bollore boards welcome Vivendi offer, to enter talks - The board of directors of Bollore and Societe Industrielle et Financiere de l'Artois, as well as the Supervisory Board of Compagnie du Cambodge, met today and reviewed the indicative offer submitted by Vivendi to acquire the 59.69% stake held by Groupe Bollore in Havas at a price of EUR9.25 per share ex dividend of EUR0.18which will be paid on 13 June 2017. This offer values the stake of Groupe Bollore at EUR2.36B. Given the financial terms, the strategic rationale and the development prospects implied by Vivendi's indicative offer for the 20,000 employees of Havas, the boards of Groupe Bollore have welcomed it and have decided to enter into discussions with Vivendi.

11:52 EDT NeuroMetrix announces 1-for-8 reverse split - NeuroMetrix announced a one-for-eight reverse split of its common stock effective as of Thursday, May 11, 2017. The shares underlying the company's outstanding options and warrants will also be adjusted accordingly. The reverse stock split is intended to increase the per share trading price of the company's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on the NASDAQ Capital Market. As a result of the reverse stock split, every eight shares of the Company's common stock issued and outstanding prior to the opening of trading on May 12, 2017 will be consolidated into one issued and outstanding share, with no change in the nominal par value per share of $0.0001. No fractional shares will be issued as a result of the reverse stock split. Shareholders who otherwise would be entitled to receive a fractional share in connection with the reverse stock split will receive a cash payment in lieu thereof. Trading of the company's common stock on the NASDAQ Capital Market will continue, on a split-adjusted basis, with the opening of the markets on Friday, May 12, 2017, under new CUSIP number 641255708.

11:38 EDT InterDigital receives cash, commitments in agreement with Microsoft - InterDigital (IDCC) disclosed earlier today that it entered into a Settlement Agreement and Release of Claims with Microsoft (MSFT) pursuant to which the parties have agreed to terms for resolving all of their existing disputes, and entered into a framework for future discussions for a patent license agreement and regarding technology collaboration in key areas. Pursuant to the agreement, in exchange for cash and other commitments from Microsoft, InterDigital has agreed to a limited release on the past sales of certain Microsoft products, including Nokia terminal units sold during a limited period of time. InterDigital and Microsoft also have agreed to terms for dismissal by them and Nokia (NOK) of all outstanding litigation and other proceedings among these companies and their affiliates. InterDigital this morning also provided guidance for its sales in Q2. The stock in late morning trading is up 10c to $86.50.

11:33 EDT Wells Fargo sees $2B of annual expense savings by year-end 2018 - Wells Fargo sees $2B of annual expense savings anticipated by year-end 2018, and those savings will help offset investment spending that is already in the bank's run-rate. Wells Fargo expects an additional $2B in annual expense savings by year-end 2019; these savings are projected to go to the "bottom line."

11:30 EDT Textron strength continues amid Lockheed takeover speculation - Shares of Textron (TXT) have continued to move higher and built upside momentum after traders circulated chatter that Lockheed Martin (LMT) may be interested in acquiring the company. The Fly, in fulfilling its mission of explaining stock movement, often comes across the many unconfirmed rumors being passed through trading desks and social media platforms. On the occasion that rumors or speculation appear on The Fly's news feed, it should be viewed not as giving credence to the conjecture, rather as simply highlighting its impact on the stock prices of the companies involved. Shares of Textron have risen $1.40, or 3%, to $48.28 and are near their session highs in late morning trading.

11:08 EDT Wells Fargo CFO says net interest income was 56% of total revenue in Q1 - Says 2016 revenue up 5% from 2014 on growth in net interest income.

11:04 EDT Boeing reports 10 new orders in weekly update - Boeing reported 10 new orders in the weekly update posted on its website from WestJet for 10 787s. In the changes category, says reduced 737 orders by 15. Year to date information: 737 net orders: 69 NG and 93 MAX; 777 net orders: 9 777 and 0 777X.

11:01 EDT Chipotle names Scott Boatwright as chief restaurant officer - Chipotle Mexican Grill announced that it has hired Scott Boatwright as chief restaurant officer, a position where he will work with the company's senior restaurant leadership team to oversee restaurant operations for Chipotle's nearly 2,300 North American restaurants. Boatwright comes to Chipotle from Arby's Restaurant Group, where he served as senior vice president of operations. He joins Chipotle effective May 30.

10:49 EDT Wells Fargo CEO says aware of shifting consumer prefernces - Says consumer strategy will be transformative. Pursuing a customer experience that is based on "ease of use." The CEO cites acceleration of digital approach to improve transparency and engage customers. The bank is pivoting from a sales orientation to a more customer satisfaction approach. The CEO cites the use of fintech to engage customers and their experience.

10:34 EDT Macy's CFO says sees continued pressure on merchandise margin

10:32 EDT Delta Air Lines sees fuel prices $1.70-$2.00 per gallon - Delta Air Lines announced that fuel prices are projected to be $1.70-$2.00 per gallon based on forward curve from 2017 to 2020.

10:30 EDT Caesars announces 'important rulings' from New Jersey gaming regulators - Caesars Entertainment and Caesars Entertainment Operating Company, or "CEOC", announced that the New Jersey Casino Control Commission ruled on matters related to the restructuring of CEOC. The Commission ruled that the entities that will own the real property assets of Caesars Atlantic City and Bally's Park Place will be licensed as casino service industry enterprise licensees in connection with serving as landlords under a Lease Agreement. The Commission also approved the Lease Agreement between these entities and Caesars Atlantic City and Bally's Park Place. Further approvals of matters required to complete the restructuring and the merger of Caesars Entertainment and Caesars Acquisition Company are pending before the New Jersey Division of Gaming Enforcement and the Commission. Caesars Entertainment anticipates these rulings to be forthcoming by early third quarter of 2017. "These rulings are important milestones in the ongoing efforts to complete CEOC's restructuring," the company stated.

10:26 EDT Dow Chemical to invest $4B in U.S. over five years starting in 2020 - Dow Chemical announced its next phase of investments over the next five years to "further enhance its competitive advantage and deliver earnings growth." It states, "These investments will stimulate economic activity, primarily in the United States, while also creating a significant number of jobs tied to state-of-the-art manufacturing and infrastructure investments. The Company also continues to accelerate its efforts to train and educate the workforce and close the skills gap for tomorrow's manufacturing careers." The projects announced today extend Dow's U.S. growth investments to more than $12B over a 10-year period and are expected to employ approximately 5,500 workers at peak activity, as well as 300 permanent jobs. "Investments in the United States will support the largest job creation, reaching approximately 3,500 construction jobs and 200 full-time technical, vocational and professional careers," Dow said. The investments announced today are expected to come online in a phased manner, beginning in 2020 and will require estimated capital expenditures of approximately $4B spread over the next five years.

10:24 EDT Macy's: Current model too heavily weighted to promotional marketing - Says mobile, digital business growing at a strong pace.

10:20 EDT Macy's CEO says U.S. 'over-retailed' compared to other markets - Notes that these are "unusual, challenging times" for mall-based retailers. Says changes are secular, not cyclical. Says has known "for some time" that the U.S. is over-retailed compared to other markets, not surprising to see contraction in retail square footage. Says to introduce new marketing strategy in Q3. Says company doesn't have "head in the sand."

10:18 EDT Dow announces updated transition timing of chairman and CEO Andrew Liveris - The Dow Chemical Company (DOW) announced an update to the transition of Chairman and CEO Andrew Liveris, to reflect that he will serve as Executive Chairman of DowDuPont from closing of the DowDuPont merger transaction through April 1, 2018, at which time he will become Chairman through July 1, 2018, at which time he will retire from the company and the Board of Directors. "Given the complexity, unique structure and Andrew's role as a key architect of this transaction, the Dow Board believes that the continuity of leadership will best serve our shareholders during this critical time of transition. This enables us to achieve the full value-creation promise behind the merger and subsequent intended spins," said Jeff Fettig, Dow's Lead Independent Director and current Chairman and CEO of Whirlpool (WHR).

10:09 EDT DuPont, Dow Chemical say combined board to consist of 16 directors - DuPont (DD) and The Dow Chemical Company (DOW) announced the members of the Board of Directors for the proposed merger of equals transaction of the two companies. As determined by the merger agreement, the DowDuPont Board will consist of 16 directors - eight current Dow directors and eight current DuPont directors, as follows: From Dow: Andrew N. Liveris, Chairman and CEO, The Dow Chemical Company; Jeff M. Fettig, Chairman and CEO, Whirlpool Corporation (WHR); James A. Bell, Former CFO, Boeing (BA); Raymond J. Milchovich, Former Chairman and CEO, Foster Wheeler (FWLT); Paul Polman, CEO, Unilever (UN, UL); Dennis H. Reilley, Non-Executive Chairman, Marathon Oil Corp. (MRO); James M. Ringler, Chairman, Teradata Corporation (TDC); Ruth G. Shaw, Former Group Executive, Public Policy and President, Duke Nuclear (DUK). From DuPont: Edward D. Breen, Chair and CEO, DuPont Alexander M. Cutler, Former Chairman & CEO of Eaton (ETN); Lamberto Andreotti, Former Chair of the Board and CEO of Bristol-Myers Squibb (BMY); Robert A. Brown, President of Boston University; James L. Gallogly, Former Chairman of the Management Board and CEO of LyondellBasell Industries N.V. (LYB); Marillyn A. Hewson, Chairman, President, and CEO of Lockheed Martin (LMT); Lois D. Juliber, Former Vice Chairman and COO of Colgate-Palmolive (CL); Lee M. Thomas, Former Chairman and CEO of Rayonier (RYN). The appointments will be effective upon completion of the proposed merger transaction. While both companies work toward closing, the DuPont and Dow boards continue to advance the governance structure for DowDuPont. Identified priorities of the DowDuPont Board include fulfilling governance and compliance requirements, and undertaking, as soon as practicable, a comprehensive review of the portfolios and their alignment, the total synergies and the time to spin each of the divisions. These priorities have been established in anticipation of the intended separation of DowDuPont into independent, publicly-traded companies through tax-efficient spin-offs.

09:43 EDT Parexel rises at open after Starboard discloses stake - Shares of Parexel are up 43c, or 0.58%, to $75.15 in early trading after activist investor Starboard Value disclosed in a regulatory filing last night that it holds a 5.7% stake in the company. In its filing, Starboard said it believes "there is a substantial opportunity" to improve the company's operating margins given the large disparity in its margins versus its best-in class peers. "Based on recent press reports, the Reporting Persons understand that the Issuer may be working with investment bankers to explore a sale of the Issuer. The Reporting Persons believe that if the Issuer runs a legitimate, robust process to explore strategic alternatives, there would be significant strategic and financial buyer interest in such sale process," Starboard added in the filing.

09:30 EDT Ford says watching inventory levels 'like a hawk' - Says "very comfortable" with current inventory levels.

09:24 EDT Wells Fargo sees saving $2B annually by year-end 2018, further $2B by end-2019 - Wells Fargo, in investor day slides, said it expects to grow net interest income year-over-year in 2017 by low to mid single percentage points, but "results will be influenced by a number of factors." Wells Fargo also said it expects efficiency initiatives to reduce expenses by $2B annually by year-end 2018 and that those savings will support investment in its business. The bank added that it expects an additional $2B in annual expense reductions by the end of 2019, adding those savings are "projected to go to the 'bottom line'".

09:23 EDT Marrone Bio enters into master distribution agreement with Jet Harvest Solutions - Marrone Bio Innovations announced that the companies have entered into a master distribution agreement to market Jet Harvest's Jet-Ag. Jet-Ag is effective against bacteria, mold and yeasts and can be used by growers to combat a wide range of plant pathogens to help reduce microbial levels and disease problems in the agricultural, horticultural and turf industries.

09:21 EDT Ford says has made 'major commitment' to electrification - Says plans to invest more than $4B in electric vehicles over next five years.

09:18 EDT Buffalo Wild Wings shareholder Marcato issues letter to shareholders - Buffalo Wild Wings shareholder Marcato Capital Management, a San Francisco-based investment manager which beneficially owns approximately 6.1% of the outstanding common shares of Buffalo, mailed a letter to BWLD shareholders requesting that shareholders vote for its board nominees at the company's Annual Meeting on June 2. The letter states, among other things, "The guest experience has significantly degraded. We are aware of how poor food quality, deficient customer service, and a lack of menu and technological innovation have alienated core customers. Management has communicated no credible strategic plan to address serious issues facing the business (...) Financial performance is woefully inadequate. In recent years, under current leadership, earnings growth has stalled and the company's stock has underperformed because of what we believe have been misguided strategies to grow sales at the expense of profits and returns, failed execution, and the Board's complete lack of oversight and accountability as the business went from leader to laggard (...) BWLD management is years behind on nearly every strategic priority it has outlined (...) Not a single executive and only one director on one occasion has ever executed an open-market purchase of BWLD stock (...) If the leaders of Buffalo Wild Wings don't believe in the long-term value of BWLD stock, why should shareholders believe in them? (...) On the other hand, Marcato and its affiliates beneficially own 6.1% of BWLD's common stock (...) Our recommendations are focused on a multi-year plan of improvement that is readily achievable with the right combination of management talent, incentives, and board oversight (...) The company has hindered our ability and legal right to communicate with other shareholders, appointed three new Board members unilaterally and without shareholder input, and suspiciously changed its peer group multiple times when presenting relative performance (...)".

09:16 EDT Granite City Food & Brewery names Richard Lynch as CEO - Granite City Food & Brewery announced that Richard H. Lynch, a member of its Board of Directors, has been appointed as the company's CEO. Interim CEO, Rob Doran, will continue to serve as a member of Granite City's Board of Directors.

09:08 EDT BMGI delivers letter to Federated Investors CEO - BMGI announced that on May 5 it delivered a letter to the CEO of Federated Investors. The text of the letter said: "We were served with a subpoena at 4 p.m. on May 1 by Jones Day acting on your behalf seeking information relating to a breach of contract dispute between Federated Investors and its former employee Michael Jones. In the 12-page subpoena you demand that we produce more than seven years of documents and that one of our senior investment personnel appear for a live, videotaped deposition. Federated's decision to subpoena the Bill & Melinda Gates Foundation Trust, a former client, on a matter that does not in any way involve us, is inappropriate and reflects a profound lack of sound business judgment. This matter demands your immediate attention...That you would take this irresponsible step of subpoenaing a former client, who is uninvolved in the matters in question and has done nothing wrong, reflects a fundamental lack-of-respect for all who have entrusted Federated with their assets. The effort it would take to comply with your subpoena and fruitlessly search for relevant documents would also waste valuable time and resources that would otherwise be directed toward achieving our core mission, which is to preserve and enhance the necessary funding for the Bill & Melinda Gates Foundation's vital philanthropic works throughout the world. Please be advised that, based on your and your counsel's ill-advised and counter-productive conduct, we will not consider Federated for any future business. We demand that you instruct your counsel to immediately withdraw the subpoena, and allow both of our organizations to focus on things that truly matter. If we have not received confirmation from you or your counsel that you are doing so within twenty-four hours we will proceed on the basis that you have chosen to continue to pursue the subpoena despite our demand."

09:06 EDT IBM's Weather Channel adds third-party service options to mobile website - IBM's The Weather Channel, part of The Weather Company, announed a partnership with the Button platform enabling mobile integrations with brands including ridesharing service Uber, activities marketplace Groupon, hospitality and reservations technology company Resy, food and alcohol delivery service delivery.com, and food ordering platform Caviar. Through these integrations, The Weather Channel mobile site will now provide complementary services alongside weather data. Users will now see relevant Buttons alongside weather data on The Weather Channel mobile site.

09:03 EDT Twitter partners with NFL for live content - Twitter and the National Football League announced a new multiyear deal to deliver official NFL video and other types of content around the world daily, year-round. The NFL and Twitter will offer brands the opportunity to advertise on official NFL content created specifically for the Twitter platform. The NFL will produce a 30-minute live digital show that will air on Twitter five days per week during the NFL season. The NFL will utilize Periscope and Twitter for live pre-game access from each of its primetime game windows, as well as other key match-ups during the season. The NFL will continue to program a full slate of highlights, breaking news and analysis on Twitter.

09:01 EDT Greenlight: GM can unlock value by splitting stock into two classes - Greenlight Capital, which owns 3.6% of the common stock of General Motors, making it GM's fifth largest public shareholder, released a detailed presentation to GM's shareholders in connection with its nomination of three directors for election to the Board of Directors at GM's Annual Meeting of Shareholders, scheduled to take place on June 6, 2017. The presentation explains how GM can unlock substantial value by adopting Greenlight's proposal to split GM's common stock into two classes: one that would receive the current dividends and one that would participate in the remaining earnings and cash flows and future growth of the Company. The presentation also details the qualifications of Greenlight's director nominees and the rationale for bringing a fresh perspective and new ideas to GM's Board. In the presentation, Greenlight highlights and further discusses several key points, including: GM is substantially undervalued and has the lowest price-to-earnings ratio of any company in the S&P 500 index; Greenlight believes implementing the proposal would result in a 26% to 76% increase in GM's share price; The proposal would not impact GM's existing financial policy or operational strategy; The credit rating red herring, in which GM is attempting to manipulate both the rating agencies and its own shareholders to protect the status quo; Greenlight's nominees would bring substantially more capital markets understanding, financial sophistication and shareholder value-creation experience to the Board than the three incumbent directors they would replace; After years of barely generating any return for shareholders, GM needs directors with demonstrable track records of driving significant shareholder returns.

08:59 EDT Numerex announces renewal of contract with Charlotte-Mecklenburg PD - Numerex announced the renewal of a multi-year contract with the Charlotte-Mecklenburg Police Department through the City of Charlotte, N.C. The contract agreement will provide Numerex's state of the art offender monitoring and tracking solution, Omnilink, to enable real-time visibility of offenders who are under a court order to be tracked and monitored electronically. The contract renewal provides up to five years of offender tracking services with an approximate value of $2 million.

08:54 EDT Ford says will launch eleven new vehicles in 2017 - Says will electrify 13 new vehicles globally in next five years. Says biggest strategic shift in company history is "well underway."

08:50 EDT Obalon gets regulatory approvals to commercialize in some Middle East markets - Obalon Therapeutics announced regulatory approvals in select international markets. Obalon has received notification that it has obtained the necessary regulatory approvals in select Middle East markets to commercialize the Obalon six-month balloon and the associated inflation dispenser. Obalon intends to fulfill an initial order to its Middle East distributor, Bader Sultan, during the second quarter of 2017.

08:47 EDT Kohl's sees opportunity to capture sales from competitors' closing stores - Kohl's (KSS) sees significant opportunity to capture sales from competitors' stores that are closing. TheFly notes that competitors closing stores include Macy's (M) and J.C. Penney (JCP). Says store optimization strategy "the right one." Kohl's is down 1.4% in premarket trading as its earnings call continues.

08:45 EDT Air Products to supply JHICC's new memory fab in South China - Air Products has been awarded the industrial gases supply for the new memory fab of Fujian Jinhua Integrated Circuit , or JHICC. The fab is located in the Fujian (Integrated Circuit Industrial Park, Quanzhou City of Fujian Province. Air Products will build a nitrogen plant and leverage its existing liquid bulk supply capability to supply a broad range of ultra-high purity gases.

08:41 EDT Kohl's CEO says 'notable improvement' in March-April combined sales, traffic - Kohl's (KSS) says saw "relatively dramatic" improvement in sales trends throughout Q1. Says February was most challenging month of the quarter, says transactions in March and April improved almost 600bps from February. Still sees annual tax rate of 37.5%, sees inventory down low to mid single digits for the year. CEO Kevin Mansell says there was a "notable improvement" in March-April combined period in sales, traffic; says sales in February declined high single digits and improved to down 1% in the March-April combined period. Says seeking long-term sustainable expense reductions to lower annualized spend; will share size, scale of this effort in Q2 earnings report in August. Says Nike (NKE) continued growth trajectory, with sales up high single digits in Q1; says overall active sales delivered mid teen growth rate for Q1.

08:37 EDT XBiotech Senior VP of Operation Thornburg resigns - In a regulatory filing, XBiotech disclosed that on May 5, the company's Senior Vice President of Operation Kelly Thornburg announced his resignation from his position at XBiotech, effective immediately.

08:35 EDT Elliott says 'welcomes' Glass Lewis support for Arconic nominees - Elliott Management Corporation, which manages funds that collectively beneficially own a 13.2% economic interest in Arconic, welcomed the decision by Glass, Lewis & Co., an independent proxy advisory firm, to recommend that all Arconic shareholders vote the BLUE proxy card in favor of real change at Arconic's upcoming Annual Meeting of Shareholders to be held on May 25, 2017. Glass Lewis recommended that clients vote on the BLUE proxy card for all four of the highly qualified, independent shareholder nominees: Chris Ayers, Elmer Doty, Bernd Kessler and Patrice Merrin. Elliott welcomes the recommendation of Glass Lewis for these shareholder nominees and urges all Arconic shareholders to deliver real change on May 25.

08:34 EDT Veracyte 's Percepta genomic classifier featured in Journal of Thoracic Oncology - Veracyte announced data on the cost-effectiveness of the Percepta Bronchial Genomic Classifier published in the Journal of Thoracic Oncology. According to the company, these data suggest that "use of the Percepta classifier in lung cancer screening and diagnosis can meaningfully reduce invasive procedures and associated costs, and is cost-effective across a range of assumptions". The Percepta classifier is used to resolve inconclusive bronchoscopy results in patients undergoing evaluation for potentially cancerous lung nodules or lesions. Investigator found that use of the Percepta classifier following an inconclusive bronchoscopy reduced invasive procedure rates by 28% at one month and 18.3% at two years, compared to use of bronchoscopy alone. They also found that the incremental cost-effectiveness ratio, the primary metric used in health economics to assess the value of an intervention, was $15,052 per quality-adjusted life years.

08:18 EDT Teva sees non-core asset sales generating 'significantly' over prior $1B target - Teva Interim CEO Yitzhak Peterburg said that Teva has engaged Morgan Stanley to serve as its financial adviser as it pursues the sale of its global Women's Health business and selected Bank of America to serve as financial adviser to sell its Oncology and Pain business in Europe. Teva expects the sale process for both businesses to commence in the coming weeks, with the distribution of marketing materials to interested buyers. "We believe we will be able to complete these transactions by the end of the year, subject to evaluation of pricing proposals and board approvals. We believe that the proceeds from the sale of both businesses as well as additional asset sales will be significantly in excess of our previously identified target of $1B," Peterburg said on the company's Q1 call.

08:13 EDT Teva says headcount down 5,000 since close of Actavis transaction - Teva's Yitzhak Peterburg said the company has reduced headcount by approximately 5,000 people since the close of Actavis generics transaction and expects further reductions through the end of 2017.

08:11 EDT Fiesta Restaurant stockholder JCP Investment comments on Q1 performance - Fiesta Restaurant Group stockholders JCP Investment Management, together with its affiliates and the other participants in its solicitation, with aggregate ownership of approximately 8.6% of the company's outstanding shares, commented on Fiesta's Q1 earnings announcement and urged stockholders to vote for its nominations for the board of directors. JCP claimed to be "disappointed, but not surprised, by the company's Q1 results announcement. Beyond Fiesta's poor reported performance, including a 10.7% decline in April comparable restaurant transaction counts at Pollo Tropical from the same period in 2016, CEO Richard Stockinger highlighted a number of alarming issues plaguing Fiesta's operations (...) The fact that the Board wasted more than $70M investing in new markets while neglecting the core Florida market and failing to maintain these once highly profitable stores demonstrates the need to hold the incumbent directors accountable who authorized this value destruction (...) We remind stockholders that not one non-executive director has stepped down from the Board despite the company's continued underperformance".

08:08 EDT Ocular Therapeutix presents Phase 3 data for Dextenza at ARVO meeting - Ocular Therapeutix presented ocular pain data from a pooled analysis from three Phase 3 clinical trials evaluating the efficacy and safety of Dextenza 0.4 mg for intracanalicular use, for the treatment of ocular pain and inflammation following cataract surgery, at the Association for Research in Vision and Ophthalmology Annual Meeting in Baltimore, MD. The U.S. Food and Drug Administration has set a target action date under the Prescription Drug User Fee Act of July 19 for a decision regarding the potential approval of Dextenza. The upcoming PDUFA date is for a New Drug Application for the treatment of ocular pain following ophthalmic surgery based on a Phase 2 study and two Phase 3 trials. The third and most recent Phase 3 study results are not currently being evaluated by FDA as part of the current NDA. The pooled analysis includes data from all three Phase 3 trials, in which 79% percent of Dextenza patients reported no pain at day eight compared to 56.9% of the placebo patients. Across all three Phase 3 trials, a greater proportion of placebo patients experienced at least one ocular adverse event as compared with Dextenza patients. The most frequent ocular AEs were anterior chamber inflammation, increased intraocular pressure, corneal edema, and eye inflammation. There were no treatment-related serious adverse events in either group. A poster describing the results of the pooled analysis from three Phase 3 clinical trials evaluating the efficacy and safety of Dextenza was presented at the ARVO Annual Meeting: Three Phase 3 trials were pooled to evaluate the integrated efficacy of Dextenza when placed in the canaliculus of the eye for the treatment of post-surgical pain in subjects who have undergone cataract extraction with intraocular lens implantation. The pooled analysis confirmed the results of the individual Phase 3 trials. Dextenza compared with placebo vehicle insert, resulted in a significantly greater proportion of patients who reported an absence of ocular pain following cataract surgery. The company also presented other data at the ARVO Annual Meeting including plasma pharmacokinetics of Dextenza in healthy volunteers, the evaluation of a Phase 2b study for OTX-TP, the company's sustained release travoprost intracanalicular insert for the treatment of glaucoma and ocular hypertension compared to timolol drops, preclinical data on tolerability and pharmacokinetics of a six month sustained release hydrogel TKI depot for tyrosine kinase inhibitors, efficacy of a six month sustained release hydrogel TKI depot in a VEGF-induced retinal leakage model and outcomes in cataract surgery using ReSure Sealant for the intraoperative management of clear corneal incisions.

08:07 EDT Cisco announces intent to acquire MindMeld for $125M - Cisco announced its intent to acquire MindMeld, a privately held artificial intelligence company based in San Francisco. MindMeld has pioneered the development of a unique AI platform that enables customers to build intelligent and human-like conversational interfaces for any application or device. Through its proprietary machine learning technology, MindMeld delivers incredible accuracy to help users interact with voice and chat assistants in a more natural way. Cisco will acquire MindMeld for $125M in cash and assumed equity awards. The acquisition is expected to close in Cisco's fourth quarter of fiscal year 2017, following customary closing conditions and regulatory review.

08:06 EDT Aimmune enrolls first patient in RAMSES Phase 3 trial of AR101 - Aimmune Therapeutics announced the enrollment of its first patient in the Phase 3 RAMSES -- ARC007 -- clinical trial of AR101 for treatment of peanut allergy. AR101 is Aimmune's investigational biologic oral immunotherapy for desensitization of patients with peanut allergy. The Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Age 4-17 Years, or RAMSES, trial is designed to gain experience with AR101 in a real-world setting, without the use of a double-blind, placebo-controlled food challenge to confirm peanut allergy. It will assess the safety and tolerability of AR101 versus placebo. The trial follows the same up-dosing and maintenance protocol as Aimmune's ongoing Phase 3 PALISADE trial, taking place in the United States, Canada, and eight countries in Europe. RAMSES is a randomized, double-blind, placebo-controlled trial enrolling approximately 440 peanut-allergic patients ages 4-17 at multiple sites in the United States and Canada. Patient selection is based on stringent entry criteria, including a well-documented medical history of IgE-mediated reactions to peanut, skin reactivity, and analyses of peanut-specific allergic antibodies. The trial will monitor treatment-emergent adverse events during a six-month up-dosing period, and then, after unblinding, follow patients for at least six months on the maintenance dose of 300 mg of AR101 per day. Aimmune anticipates that the absence of an entry food challenge may improve the tolerability profile of AR101 in early stages of dosing by removing exposure to high levels of peanut allergen that may otherwise prime the immune system prior to treatment.

08:05 EDT Canada Goose opens 2 international flagship stores, expands ecommerce in Europe - Canada Goose Holdings announced it will open two flagship stores this fall, in London, U.K., and Chicago, U.S. At the same time, the company announced the expansion of its e-commerce channel to seven new markets including Germany, Sweden, Netherlands, Ireland, Belgium, Luxembourg and Austria.

08:04 EDT Xencor says XmAb5871 granted orphan drug designation by FDA - Xencor announced that XmAb5871 has been granted orphan drug designation by the U.S. FDA for the treatment of IgG4-Related Disease, a newly defined fibro-inflammatory autoimmune disorder that is estimated to impact up to 40,000 patients in the United States.

08:02 EDT Macy's affirms FY17 guidance

07:47 EDT Oragenics amends first milestone in collaboration agreement with Intrexon - Oragenics (OGEN) announced that it has entered into a securities purchase agreement with three accredited investors, to purchase up to $3M of Series A convertible preferred stock at a price of 25c per share. Concurrently with the Preferred Stock Financing, the company also entered into a Note Purchase Agreement with Intrexon Corporation (XON) pursuant to which the company issued a $2.4M unsecured non-convertible promissory note to Intrexon and amended the first milestone in its oral mucositis Exclusive Channel Collaboration Agreement with Intrexon. The Intrexon Note matures in two years and has a simple interest rate of 12% per annum. Proceeds from the Intrexon Note will be used to fund the company's AG013 research and clinical trials. In addition to, and as part of the Intrexon Note, the company and Intrexon agreed to amend the first milestone payment on the ECC from a $2M payment upon first dosing of a patient to a $3M payment upon the earlier of (a) dosing of the last patient, in a phase II clinical trial, and (b) the twenty four month anniversary of the dosing of the first patient in the phase II clinical trial.

07:39 EDT Dillard's reports Q1 SSS down 4% - Total merchandise sales for the 13-week period ended April 29 were $1.39B and $1.45 billion for the 13-week period ended April 30, 2016. Total merchandise sales decreased 4% for the 13-week period ended April 29. Sales in comparable stores for the period also decreased 4%. Sales of ladies' apparel notably outperformed other merchandise categories during Q1 followed by the juniors' and children's apparel category. Weaker performances were noted in cosmetics, home and furniture, and ladies' accessories and lingerie. Sales were strongest in the Western region followed by the Eastern and Central regions, respectively.

07:36 EDT Accuray's CyberKnife feauted in over 50 studies at ESTRO 36 - Accuray announced studies on the clinical use of the CyberKnife System across a range of cancer indications and stages in the cancer treatment journey. More than 50 studies were presented during poster and oral sessions at the 36th Annual European Society for Radiotherapy & Oncology Meeting in Vienna, Austria, May 5 - 9. CyberKnife stereotactic body radiation therapy is used for management of prostate cancer. Safety, efficacy, and quality of life outcomes were reported for 309 patients with low- or intermediate-risk prostate cancer receiving SBRT administered with the CyberKnife System. The study showed 97% of patients free from recurrence at five years in both risk groups. Transient decreases in bowel and urinary QOL were observed, but returned to baseline. A study evaluated the long-term results of CyberKnife prostate SBRT delivered either on consecutive days or every other day. The treatment was well-tolerated with high rates of five-year biochemical relapse free survival . Low rates of toxicity were unaffected by the treatment schedule. Long-term results of another study conducted on 329 patients with low- and intermediate-risk prostate cancer revealed that extreme hypofractionated radiotherapy delivered with the CyberKnife System is well tolerated and safe with comparable late toxicity as other treatment modalities.

07:29 EDT GOL Linhas reports April departures down 6.2% - GOL Linhas reported April total volume of departures GOL decreased by 6.2%, and the number of seats declined 5.6%, while supply increased 2.6% due to the 8.8% increase in the average stage length. Demand increased by 6.9% in the period. GOL's load factor was 79.0% in April 2017, 3.2 p.p. up over the same period of 2016. In the domestic market, GOL increased its supply by 3.2% in April over the same period the year before. Domestic demand increased by 7.4% in the month, and GOL achieved a load factor of 79.2%, 3.1 p.p. up over April 2016. In April, GOL's international market supply fell by 1.5%, while demand increased by 3.2% resulting in load factor of 78.0%, which represents growth of 3.6 p.p. in relation to the same period of 2016.

07:23 EDT uniQure announces 'successful' readministration of gene therapy in NHPs - uniQure N.V. presented data on successful repeated hepatic gene delivery with uniQure's AAV5 vector following a proprietary immunoadsorption procedure in non-human primates, or NHPs. The results describing successful sequential transduction with the two reporter transgenes were presented today in a session at the American Society of Gene and Cell Therapy 20th Annual Meeting in Washington, D.C., and highlight the progress made in readministration protocols for AAV gene transfers.

07:19 EDT Asterias' AST-OPC1 cells show 'positive' result in Phase 1/2a clinical study - Asterias announced new positive serial magnetic resonance imaging data from its ongoing AST-OPC1 SCiStar Phase 1/2a clinical trial in patients with severe spinal cord injury. For the five AIS-A patients in the SCiStar study treated with 10 million AST-OPC1 cells who also received a serial MRI scan at six months of follow-up, the serial MRI scans at six months indicated no sign of lesion cavities in any patient. For the three patients with 12 months of follow-up, serial MRI scans continued to indicate no signs of lesion cavities. The MRI results are supportive of the extensive pre-clinical data on AST-OPC1 showing that AST-OPC1 cells durably engraft and help prevent cavitation at the injury site.

07:14 EDT STAAR Surgical's EVO+ Optic granted CE Mark approval - STAAR Surgical has received CE Mark for its EVO+ Visian ICL with Aspheric Optic, for commercialization in the European Union from its Notified Body, DEKRA. The EVO+ Visian ICL with Aspheric Optic is a surgically implanted lens which works in harmony with the patient's eye to correct vision. Unlike traditional contact lenses that are placed on the surface of the eye, the EVO Visian ICL family of lenses is positioned inside the eye between the iris and the natural lens where it stays indefinitely.

07:11 EDT EnSync signs purchase agreement to provide electricity to Hawaiian development - EnSync announces the signing of a power purchase agreement for the Kalaeloa Makai Residential Development in Oahu, Hawaii. The residential development comprises more than 200 units of varying sizes, and features solar PV to be deployed atop buildings of nearly all three and four-bedroom units. The solar electricity project includes a PPA term of 20 years.

07:09 EDT Teva reports Q1 Generic revenue of $3.1B, Specialty revenue of $2.0B - Generic medicines revenues in the first quarter of 2017 were $3.1B, an increase of 24% compared to the first quarter of 2016, reflecting the inclusion of the Actavis Generics business. Specialty medicines revenues in the first quarter of 2017 were $2.0B, down 6% compared to the first quarter of 2016. The decrease in specialty medicines revenues compared to the first quarter of 2016 was primarily due to lower sales of CNS and respiratory products, partially offset by a payment of $75M received in connection with the agreement to sell royalties and other rights in Ninlaro to a subsidiary of Takeda. Global revenues of Copaxone were $970M in the first quarter of 2017, a decrease of 4% compared to the first quarter of 2016.

07:06 EDT Teva pursuing sale of certain non-core assets to pay down debt - Interim CEO Yitzhak Peterburg said: "In the three months since I have stepped in as the Interim CEO, we have worked tirelessly to ensure that we extract synergies related to the Actavis Generics transaction, drive additional efficiencies throughout the organization, support cash generation, pay down debt, deliver on the promise of the specialty pipeline and execute key generic launches. We are pleased that the transaction synergies and additional cost reductions are on track, and we now expect to realize cumulative net synergies and cost reduction of approximately $1.5B by the end of 2017, an increase of $200M compared to our previous guidance. Notably, we have reduced our gross debt by $1.2B in the quarter. We are also pursuing the sale of certain non-core assets, including our global Women's Health business and our Oncology and Pain business in Europe, to pay down debt. In Specialty, we have received several important approvals, including the recent approval and launch of AUSTEDO for Huntington's disease."

07:03 EDT GTx announces acceptance of abstract of Phase 2 GTx-024 data for presentation - GTx, Inc announced the acceptance of an abstract on preliminary clinical data from its ongoing, open-label, Phase 2 proof-of-concept clinical trial of enobosarm -- GTx-024 -- evaluating enobosarm 3 mg in postmenopausal women with stress urinary incontinence.The clinical trial is the first study evaluating an orally administered selective androgen receptor modulator for SUI. The clinical data will be reviewed during a podium presentation at the International Continence Society Annual Meeting during the Session on Female Pelvic Floor Dysfunction, being held on September 13, 2017, in Florence, Italy. Enrollment in the Phase 2 proof-of-concept clinical trial of 3 mg of enobosarm in women with SUI is ongoing. This is the first clinical trial to evaluate a SARM for SUI. The Company believes that developing an oral therapy to treat the large number of women who face a diminished quality of life from stress urinary incontinence presents a unique commercial opportunity, especially since current therapies may sometimes involve invasive procedures.

07:03 EDT Norgine to acquire all outstanding shares of Merus Labs for $1.65 per share

06:55 EDT Synthesis Energy secures technology license agreement for project in Australia - Synthesis Energy has entered into a definitive Technology License Agreement with Australian Future Energy Pty for a large-scale project to be located in Australia. Based on the terms of the agreement, SES will receive fees based on the licensed capacity for the project, and for the Process Design Package, totaling $27M. In addition to the Technology License and PDP, SES will immediately begin providing technical services to AFE related to the development of the project. It is expected that the project will purchase proprietary equipment from SES which, based on the license capacity of the project, could be valued at approximately $120M and would be contracted soon after completion of the PDP. The entire package of technology, services and equipment is expected to provide SES with top line revenue of approximately $150M.

06:47 EDT Verizon to enter definitive agreement to buy Straight Path for $184 per share - Straight Path Communications (STRP) announced that it will sign today a definitive merger agreement under which Verizon Communications (VZ) will acquire Straight Path for $184.00 per share -- reflecting an enterprise value of approximately $3.1B -- in an all-stock transaction that is intended to qualify as a tax-free reorganization. Concurrently therewith, Verizon will pay on behalf of Straight Path a termination fee of $38M to AT&T (T). The transaction has been approved by the boards of directors of both Straight Path and Verizon. Straight Path also announced that it will terminate the previously announced definitive agreement and plan of merger with AT&T and Switchback Merger Sub Inc., dated as of April 9, 2017. As previously announced, the Straight Path board of directors determined, in good faith, after consultation with its financial advisors and outside legal advisors, that the transaction with Verizon constituted a Superior Proposal under the AT&T Merger Agreement. AT&T informed Straight Path that after much deliberation, it has determined not to make any new bids or proposals to Straight Path or to propose any amendments to the AT&T Merger Agreement. The acquisition of Straight Path for $184.00 per share in Verizon stock, implies a premium of 486% to the closing price of Straight Path common stock of $31.41 on January 11, 2017, the day before Straight Path announced its FCC settlement and strategic alternatives process, and 404% premium to the closing stock price of $36.48 on April 7, 2017, the business day prior to entry into the AT&T Merger Agreement. Stock consideration received by Straight Path stockholders will be based on a variable number of Verizon common stock issued at transaction close to ensure fixed consideration of $184.00 per share. The companies anticipate a closing within nine months, subject to FCC review. The transaction is supported by Straight Path's majority shareholder, Howard Jonas, who has entered into a voting agreement with Verizon and agreed to vote his Class A shares in support of the transaction, subject to certain limitations. Evercore served as exclusive financial advisor to Straight Path and Weil, Gotshal & Manges LLP served as company counsel on this transaction. Debevoise & Plimpton LLP served as counsel to Verizon on this transaction

06:46 EDT Verizon to enter definitive agreement to buy Straight Path for $184 per share

06:36 EDT SAIC awarded $61M task order by SSC Atlantic - The Space and Naval Warfare Systems Center Atlantic awarded Science Applications International Corp. a task order to perform command, control, communications, computers, intelligence, surveillance, and reconnaissance engineering upgrades and integration for tactical vehicles. The task order has a one-year base period of performance, a six-month option, and a total award value of approximately $61M if the option is exercised. Work will be performed at Fort Bragg, North Carolina; Charleston, South Carolina; Wahiawa, Hawaii; and Vicenza, Italy.

06:29 EDT Muddy Waters call on investors to 'scrutinize' Silvercorp Metals - Muddy Waters Research said via Twitter after Silvercorp Metals announced its common shares have been authorized for listing on the NYSE MKT, "Apparently there's very little justice in the world. Investors should scrutinize $SVM very very closely."

06:19 EDT BT Group says to cut about 4,000 roles in cost transformation program - BT says it is expanding and accelerating areas of its cost transformation program. "We are simplifying our central Group Functions and our internal service unit, Technology, Service & Operations to improve the effectiveness and efficiency of the services and infrastructure delivered to our lines of business. We are also restructuring the Global Services organization, as described above, and accelerating ongoing transformation programs in other lines of business. We anticipate that these transformation programs will save in total around GBP 300m over two years, with a restructuring charge of around GBP 300m over the next two years, with most of this being incurred in 2017/18. This restructuring cost will be treated as a specific item. These changes will clarify accountabilities, remove duplication and improve efficiencies, removing around 4,000 roles mainly from managerial and back office areas. The cost savings will provide headroom to offset market and regulatory pressures and support increased investment in delivering great customer experience and leading networks."

06:15 EDT WildHorse Resource provides highlights of Eagle Ford properties acquisition - Key acquisition highlights: Approximately 111,000 net acres (95% held by production) in Burleson, Brazos, Lee, Milam, Robertson, and Washington Counties next to WRD's existing acreage position. Approximately 7.6 MBoe/d of net production for fourth quarter 2016 consisting of approximately 72% oil and 89% liquids from 68 Eagle Ford, 299 Austin Chalk, 19 Buda/Georgetown operated wells. 949 net Eagle Ford locations and 22.9 MMBoe of proved developed producing reserves (73% oil and 88% liquids). Leverage neutral transaction structure maintains a pro-forma net debt to annualized EBITDAX target of 2.0x or less. Transaction consideration is $625 million including approximately $556M of cash to APC (APC) and 6.3M shares of WRD (WRD) common stock valued at approximately $69M to KKR (KKR). In conjunction with the transaction, The Carlyle Group (CG), through its U.S. buyout fund Carlyle Partners VI, has agreed to purchase $435M of Series A Perpetual Convertible Preferred Stock from WRD. The remainder of the acquisition price is to be funded by borrowings under WRD's revolving credit facility.

06:09 EDT WildHorse Resource raises FY17 CapEx view to $550M-$675M - With 36 wells of the existing 2017 development plan surrounding the acquisition acreage, WRD will begin drilling the new position almost immediately. In addition, WRD's updated 2017 capex guidance has been increased to $550M-$675M with some capital immediately reallocated to drilling on the acquisition acreage. The drilling program has also increased by 10 gross wells to between 100 - 120 gross spuds in 2017. The number of gross wells brought online has increased by 5 wells to between 85 and 105 gross wells in 2017. The announced acquisition will also increase the working interest of our 2017 and 2018 development programs. Several of the additional wells will be on the acquired acreage in addition to the 36 adjacent wells already planned prior to the acquisition. Full year 2017 production guidance increased by approximately 4.0 MBoe/d to 27.0 - 31.0 MBoe/d comprised of 1.0 MBoe/d as a result of WRD well performance and 3.0 MBoe/d as a result of the acquisition expected to close on June 30, 2017. Pre-acquisition production guidance increased by 4% due to well performance.

06:07 EDT Newmont Mining investing $109M in Continental Gold - Newmont Mining announced an agreement to invest approximately $109M for 19.9% ownership of Continental Gold, supporting near-term development of the high grade Buritica gold project in Colombia. The investment also covers three other exploration assets in this prospective gold district. The Buritica deposit consists of two major vein systems that remain open along strike and at depth. Continental has declared proven and probable reserves of 3.7 million ounces of gold averaging more than eight grams per ton. Construction of the underground mine and process plant is expected to begin in 2H17 with commercial production targeted for early 2020. Newmont has agreed to purchase 37.38 million common shares of Continental in a non-brokered private placement at a price of C$4.00 per share. Closing of this purchase is expected by May 18. Terms of the investment agreement include Newmont's right to participate in future equity issuance to maintain its ownership stake; the two companies establishing joint technical and sustainability committees and a strategic exploration alliance; and Newmont holding a seat on Continental's Board of Directors.

06:05 EDT Moody's downgrades six Canadian banks, citing tough operating environment - Moody's Investors Service yesterday downgraded the Baseline Credit Assessments, the long-term ratings and the Counterparty Risk Assessments of six Canadian banks and their affiliates, reflecting Moody's expectation of a more challenging operating environment for banks in Canada for the remainder of 2017 and beyond, that could lead to a deterioration in the banks' asset quality, and increase their sensitivity to external shocks. The banks affected are: Toronto-Dominion Bank (TD), Bank of Montreal (BMO), Bank of Nova Scotia (BNS), Canadian Imperial Bank of Commerce (CM), National Bank of Canada (NTIOF), and Royal Bank of Canada (RY). The BCAs, long-term debt and deposit ratings and CRAs of the banks and their affiliates were downgraded by 1 notch, excepting only Toronto-Dominion Bank's CRA, which was affirmed. The short term Prime-1 ratings of the Canadian banks were affirmed. All relevant ratings for these banks continue to have negative outlooks, reflecting the expected introduction of an operational resolution regime in Canada. "Today's downgrade of the Canadian banks reflects our ongoing concerns that expanding levels of private-sector debt could weaken asset quality in the future. Continued growth in Canadian consumer debt and elevated housing prices leaves consumers, and Canadian banks, more vulnerable to downside risks facing the Canadian economy than in the past." said David Beattie, a Moody's Senior Vice President.

06:03 EDT Orbital ATK reports record backlog of $9.8B - "Orbital ATK is off to a solid start in 2017. First quarter financial results were in line with our plan for the year, which is second half weighted as we previously indicated," said David W. Thompson, President and CEO. Thompson added, "Our first quarter book-to-bill ratio of 150% boosted firm backlog to a record $9.8 billion. In addition, these strong new business bookings reflected a return to our historic proportion of shorter-cycle contracts, which will help drive revenue growth this year and in 2018, following a period of robust long-cycle orders in 2015 and 2016."

05:51 EDT Tesaro - TESARO and Clinigen Group's Idis Managed Access division have partnered to launch a Managed Access Program in Europe for the investigational PARP 1/2 inhibitor, niraparib, for patients with recurrent ovarian cancer. Niraparib is currently an investigational agent in Europe and as such has not been granted approval by the European Commission. The niraparib marketing authorization application is under review by the European Medicines Agency. Niraparib was recently approved by the FDA under the brand name ZEJULA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

05:34 EDT Exxon Mobil to acquire Jurong Aromatics Corporation plant in Singapore - ExxonMobil Chemical announced that its Singapore affiliate has reached an agreement with Jurong Aromatics Corporation Pte Ltd to acquire its plant located on Jurong Island in Singapore. The plant, one of the largest in the world with an annual production capacity of 1.4M tonnes, presents operational and logistical synergies for ExxonMobil's integrated refining and petrochemical complex nearby. The company expects to complete the transaction in the second half of 2017.

04:50 EDT Silver Wheaton confirms name change to Wheaton Precious Metals - Silver Wheaton is pleased to announce that it has filed Articles of Amendment to change its name to Wheaton Precious Metals. Shareholders approved a special resolution to change the name at the company's Annual and Special Meeting of Shareholders held on May 10. The change of name to Wheaton Precious Metals is effective May 10. Concurrently, the company's wholly owned subsidiary, Silver Wheaton (Caymans) Ltd. will change its name to Wheaton Precious Metals International Ltd. It is anticipated that the company will commence trading under the symbol "WPM" on the TSX and NYSE effective on or about the opening of trading on May 16.